scholarly journals Extracorporeal membrane oxygenation in Pneumocystis jirovecii pneumonia: outcome in HIV and non-HIV patients

Critical Care ◽  
2019 ◽  
Vol 23 (1) ◽  
Author(s):  
Jonathan Rilinger ◽  
Dawid L. Staudacher ◽  
Siegbert Rieg ◽  
Daniel Duerschmied ◽  
Christoph Bode ◽  
...  
Keyword(s):  
Extracorporeal Membrane Oxygenation ◽  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Hiv Patients ◽  
Membrane Oxygenation

Favourable outcome after prolonged veno-venous extracorporeal membrane oxygenation (V-V ECMO) support for Pneumocystis jirovecii pneumonia in a renal transplant recipient

2021 ◽  
Vol 14 (4) ◽  
pp. e240004
Author(s):  
Daniel Kleinloog ◽  
Jacinta Maas ◽  
Jorge Lopez Matta ◽  
Carlos Elzo Kraemer
Keyword(s):  
Extracorporeal Membrane Oxygenation ◽  
Favourable Outcome ◽  
Pneumocystis Jirovecii ◽  
Lung Protective Ventilation ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Partial Recovery ◽  
Ventilation Strategy ◽  
Membrane Oxygenation ◽  
Protective Ventilation Strategy ◽  
History Of

A 27-year-old man, with a history of renal transplantation, presented with acute kidney failure and Pneumocystis jirovecii pneumonia. The patient developed severe acute respiratory failure and required support by veno-venous extracorporeal membrane oxygenation for a total of 59 days. During this period, the patient had extremely low tidal volumes using a lung protective ventilation strategy and intermittent prone positioning was used to optimise oxygenation. There was full recovery of pulmonary and partial recovery of renal function.

scholarly journals Serologic Responses to Pneumocystis Proteins in HIV Patients With and Without Pneumocystis jirovecii Pneumonia

2011 ◽  
Vol 57 (3) ◽  
pp. 190-196 ◽  
Author(s):  
Matthew R Gingo ◽  
Lorrie Lucht ◽  
Kieran R Daly ◽  
Kpandja Djawe ◽  
Frank J Palella ◽  
...  
Keyword(s):  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Hiv Patients

Extracorporeal membrane oxygenation in an HIV-positive man with severe acute respiratory distress syndrome secondary to pneumocystis and cytomegalovirus pneumonia

2017 ◽  
Vol 29 (2) ◽  
pp. 198-202 ◽  
Author(s):  
Deirdre Morley ◽  
Almida Lynam ◽  
Edmund Carton ◽  
Ignacio Martin-Loeches ◽  
Gerard Sheehan ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Extracorporeal Membrane Oxygenation ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Hospital Discharge ◽  
Distress Syndrome ◽  
Case Reports ◽  
Hiv Positive ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Membrane Oxygenation

The management of critically ill human immunodeficiency virus (HIV)-positive patients is challenging; however, intensive care unit-related mortality has declined significantly in recent years. There are 10 case reports in the literature of extracorporeal membrane oxygenation (ECMO) use in HIV-positive patients, of whom seven survived to hospital discharge. We describe a 33-year-old Brazilian man who presented with Pneumocystis jirovecii pneumonia and severe hypoxic respiratory failure. He developed refractory acute respiratory distress syndrome (ARDS) and was commenced on veno-venous ECMO. He was successfully decannulated following 21 days of ECMO and survived to hospital discharge. Despite poor evidence surrounding the use of ECMO in immunocompromised patients, it is evident that ECMO could represent an important rescue therapy in HIV-positive patients with refractory ARDS.

Diagnostic evaluation of serum (1, 3)-β-d-glucan levels using the Fungitec G-Test MK kit for Pneumocystis jirovecii pneumonia (PCP) in non-HIV patients

2020 ◽  
Author(s):  
Shuhei Ideguchi ◽  
Kazuko Yamamoto ◽  
Tatsuro Hirayama ◽  
Takahiro Takazono ◽  
Yoshifumi Imamura ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Autoimmune Diseases ◽  
Characteristic Curve ◽  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Negative Evidence ◽  
Hiv Patients ◽  
Systemic Autoimmune Diseases ◽  
Mk Test ◽  
Immunodeficiency Virus

Abstract Pneumocystis jirovecii pneumonia (PCP) is an opportunistic and life-threatening pulmonary infection with an increasing prevalence among individuals who are human immunodeficiency virus (HIV)-negative. Evidence regarding diagnostic testing of PCP in this patient population is insufficient. We evaluated the performance of serum (1, 3)-β-d-glucan (BDG) using the Fungitec G-test MK kit for diagnosing PCP in non-HIV patients. We retrospectively analyzed data from 219 non-HIV adult patients who underwent bronchoscopy and were tested for P. jirovecii DNA by PCR using lavage samples from the lower respiratory tract. Fifty PCP patients and 125 non-PCP patients were included. The most common underlying diseases were malignancies and systemic autoimmune diseases. Using the serum BDG Fungitec G-test MK test to diagnose PCP, the area under the receiver operating characteristic curve (AUC) was 0.924, whereas the modified cut-off value of 36.6 pg/mL had a sensitivity and specificity of 92.0% and 84.8%, respectively. The AUC for patients with systemic autoimmune diseases was 0.873, and the accuracy of serum BDG test declined when using methotrexate (MTX). In conclusion, the serum BDG test was useful for diagnosing PCP in non-HIV patients; however, the results should be carefully interpreted in case of MTX administration. Lay Summary The Fungitec G-test MK kit for measuring serum (1, 3)-β-d-glucan (BDG) levels had a sufficient diagnostic performance for Pneumocystis jirovecii pneumonia (PCP) in human immunodeficiency virus-negative patients. However, the results should be carefully interpreted in case of MTX administration.

Sign in / Sign up

Export Citation Format

Share Document